GlassScriptPhysician profile
Rosemary Fadool
NPI 1477546273
$864.44
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $12.86 · 2021: $181 · 2022: $106 · 2023: $204 · 2024: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $293.34 | 2019-2023 | |
| Hologic Sales and Service, LLC | $120.50 | 2019-2024 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Exeltis, USA INC. | $90.37 | 2023-2024 | Slynd |
| Shield Therapeutics INC | $84.11 | 2023-2024 | Accrufer |
| Coopersurgical, INC. | $62.90 | 2022-2023 | Paragard T 380a |
| Agile Therapeutics, INC. | $41.19 | 2022-2024 | Twirla |
| Astellas Pharma US INC | $32.59 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $31.78 | 2019-2023 | |
| Boston Scientific Corporation | $21.65 | 2019 | |
| Organon LLC | $19.82 | 2021-2024 | |
| Evofem Biosciences, INC. | $16.43 | 2022 | |
| Amag Pharmaceuticals, INC. | $13.18 | 2019 | |
| Duchesnay USA Incorporated | $12.76 | 2019 | |
| Therapeuticsmd, INC. | $12.54 | 2021 | |
| Lupin INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemary Fadool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.